Nutrium has closed a $12 million Series A financing round led by Vesalius Biocapital, with participation from Lince Capital, Indico Capital Partners, and Beta Capital. The funding arrives as the company’s all-in-one nutrition solution already serves millions of patients by connecting them to over 350,000 registered dietitians across more than 90 countries. This funding further cements Nutrium’s leadership in the corporate nutrition market.
The round is timely, given escalating healthcare costs driven by obesity and the surging demand for GLP-1 medications. Employers and executives are seeking sustainable, expert-led, non-pharmaceutical wellness solutions that deliver proven health improvements without the high price tags or side-effect profiles of newer drug therapies. Nutrium meets this need by offering clinically grounded nutrition care that yields measurable outcomes.
Nutrium Care, the company’s corporate nutrition benefit, delivers quantifiable financial and health returns. Corporate partners report an average threefold return on investment, a five percent reduction in participant weight within the first four months, decreased reliance on prescription medications, and enhanced employee productivity. These results come at a fraction of the cost of GLP-1 therapies and with significantly higher retention and adherence rates.
Last year, Nutrium achieved 400 percent revenue growth—a performance that attracted its latest investors. The company’s emphasis on data-driven outcomes and seamless integration into employee benefits packages has made its solution both effective and scalable. By demonstrating cost savings alongside clinical impact, Nutrium has positioned itself as a compelling alternative to drug-centric weight management programs.
Building on existing alliances with major brands such as Wellhub, Adidas, Vodafone, and Talkspace, Nutrium plans to strengthen its U.S. operations and forge strategic partnerships with health plans and consulting firms. These collaborations will enable faster adoption of nutrition benefits and deeper integration into employer-sponsored wellness offerings.
KEY QUOTES:
“Nutrition has become a business priority for companies navigating the challenges of obesity and the rapid adoption of GLP-1 treatments. With this funding, we’re ready to expand our reach, strengthen our expert network, and deliver even greater outcomes for our clients and their people worldwide.”
André Santos, CEO and co-founder of Nutrium
“At Vesalius, we are increasingly aware of the challenges associated with obesity and the need for better nutrition care, which is often overlooked as a key solution for such chronic conditions. We believe that Nutrium will be the solution of choice for employers and individuals that would like to improve their overall health. We are impressed by the growth and achievements accomplished by Nutrium, and are thrilled to be leading the Series A, supporting the Nutrium team in their goal of making the world healthier.”
Qasim Al-Zawawi, Principal at Vesalius Biocapital
“Since the start, the team at Nutrium had a clear vision about the key role that nutrition would play in health and wellbeing. We have been fortunate to back that ambition and help the team find a path to fulfill the promise of wellbeing, a key component of longevity, which is a huge and rapidly expanding market.”
Stephan de Moraes, Managing General Partner at the independent venture capital fund manager, Indico Capital Partners
